tbuckley/cabot-search huggingface dataset:
538P Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Authors: G.E. Lech, L. Tibola Marques da Silva, R. Oliveira Silva, C.M.D.P. Reis, R. Morriello
Journal: Annals of Oncology (2024)
146P Biomarkers and intrinsic/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase II study
Authors: W. Tang, J. Xu, C. Zhu, X. Li, Z. Zhu, Q. Li, Y. Xu, X. Zhang
Journal: Annals of Oncology (2024)
532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
Authors: J-B. Bachet, O. Bouche, I. Trouilloud, M.L. Garcia Larnicol, D. Vernerey, C. Boisson, V. Hautefeuille, M. Laly, Y. Rinaldi, C. Fenioux, D. Smith, J. Desrame, C. Lecaille, B. Chibaudel, J-P. Wagner, P. Texereau, A. Vienot, D. Tougeron, C. Borg
Journal: Annals of Oncology (2024)
143P Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype
Authors: E.L. Alouani, G. Roces, D. Tougeron, M. Jaffrelot, S. Pernot, T. Mazard, V. Hautefeuille, M. Ben Abdelghani, M. Dutherage, R. Cohen, F. Sclafani, M. Muller, T. Aparicio, C. Coutzac, A. Hollebecque, M. Decraecker, P. Parent, J. Taieb, R. Guimbaud, J. Selves
Journal: Annals of Oncology (2024)
805MO Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry
Authors: E. Bachy, C. Thieblemont, R. Houot, S. Choquet, G. Cartron, G. Brisou, O. Casasnovas, F-X. Gros, F. Morschhauser, F. Jardin, L. Ysebaert, D. Beziz, C. Droumaguet-Gregoire, A. Filipovics, P. Miquel, C. Oprea
Journal: Annals of Oncology (2024)
779P Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary
Authors: L. Spurgeon, G.J. Burghel, H. Schlecht, A.R. Clamp, J. Hasan, C.L. Mitchell, Z. Salih, E.R. Woodward, E. Crosbie, S. Taylor, G.C. Jayson, G.D. Evans, R.D. Morgan
Journal: Annals of Oncology (2024)
764P How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes
Authors: L.R. Haggstrom, Y.C. Lee, C.L. Scott, J.A. Ledermann, C. Gourley, I. McNeish, F. Amant, I.L. Ray-Coquard, A. Leary, A.M. Oza, A. Tinker, A. González-Martín, S.C. Cecere, N. Colombo, H. Yoshida, C. Marth, E.M. Gomez Garcia, D.S. Tan, K.N. Moore, M.L. Friedlander
Journal: Annals of Oncology (2024)
787P First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors
Authors: N. Li, J. Gong, J. Zhang, D. Liu, Y. Chen, Y. Zhang, Y. Huang, J. Wang, J. Tang, G. Li, Y. Wang, J. Wu, S. Luo, G. Lou, W. Duan, R. Huang, M. Xu, X. Hu, L. Wu, L. Shen
Journal: Annals of Oncology (2024)
770P Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial
Authors: L. Aronson, B. Thijssen, M. Lopez-Yurda, S. Koole, P. van der Leest, A. León-Castillo, R. Harkes, I. Seignette, J. Sanders, M. Alkemade, I. Kemper, M. Holtkamp, I. Mandjes, A. Broeks, M. Lahaye, M. Rijlaarsdam, D. Van Den Broek, H.M. Horlings, W. van Driel, G.S. Sonke
Journal: Annals of Oncology (2024)
801MO Efficacy and safety of a phase II study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML)
Authors: H. Tong, S. Gao, W. Yang, J. Li, Q. Yin, X. Zhao, X. Yan, S. Tu, F. Li, H. Yang, R. Hu, S. Wang, L. Ma, Z. Dong, Z. Wang, Q. Lu, W. Tian, Z. Xiao, J. Wang
Journal: Annals of Oncology (2024)
750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
Authors: C. Friedman, A. De Burgh Williams, J.S. Lopez, K. Ouali, M.R. Middleton, F. Thistlethwaite, O. Hamid, B. Izar, V. Moreno Garcia, M.L. Johnson, D. Davar, J. Martin-Liberal, P. Roxburgh, K.N. Moore, D. Olson, S. Rottey, P.B. Kirk, Y. Yuan, S. Marshall, O. Yeku
Journal: Annals of Oncology (2024)
763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
Authors: P.D. Soberanis Pina, A.M. Oza, N. Dhani, L. Wang, R. Grant, V. Garg, J-S. Lee, C. Benito, F.R. Selim, S. Arora, J. Ramsahai, J. Quintos, P. Dhanabalan, V. Bowering, B. Lam, M. Thiagarajah, A. Fortuna, T. Pugh, S. Lheureux
Journal: Annals of Oncology (2024)
806MO Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Authors: A. Ghobadi, L.E. Budde, K. Stermer, S. Ferrando-Martinez, B.H. Lee, J. DiPersio
Journal: Annals of Oncology (2024)
753P Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial
Authors: F. Blanc-Durand, N. Ngoi, N. Kaliaperumal, V. Bijin Au, N.B.S.N. Talib, R. Sng, J. Chong, C.H. Choi, J. Zhu, D. Lim, T.Z. Tan, V.Y.M. Heong, W.Y. Chay, H.S. Kim, Y.W. Lim, J-W. Kim, B.C. Tai, K. Kim, J. Connolly, D.S. Tan
Journal: Annals of Oncology (2024)
905P Validation of MYC/TP63 classification for adenocystic carcinomas of salivary glands
Authors: P. Economopoulou, I. Kotsantis, A. Kyriazoglou, M. Anastasiou, A. Pantazopoulos, G.J. Kavourakis, M. Moutafi, A. Boulouta, N. Gavrielatou, M. Kyrkasiadou, E.D. Zazas, A. Spathis, T. Pantazopoulos, N. Koufopoulos, I. Panayiotides, A. Psyrri
Journal: Annals of Oncology (2024)
751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Authors: C. Aghajanian, B. Schmalfeldt, A. Okamoto, A. Reuss, J-W. Kim, G. Marquina Ospina, A. Ayhan, V. Salutari, C. Lebreton, D. Labudovic, G. Tognon, A.M. Chudecka-Glaz, R. Berger, S. Lheureux, S. Henry, A. Burges, R.M. Wenham, S. Nishio, L. Marshall, P. Harter
Journal: Annals of Oncology (2024)
776P Liquid biopsy for the determination of homologous recombination deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study
Authors: A. Harlé, M. Husson, C. Michel, I. Hanriot, P. Gilson, J. Dardare, A. Witz, M. Betz, A. Leroux, J.L. Merlin, C. Gavoille
Journal: Annals of Oncology (2024)
761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies
Authors: B. Czogalla, F. Trillsch, F. Heitz, S. Mahner, V. Loidl, B. Aminossadati, S. Malander, N. de Gregorio, F. Selle, P. Wimberger, M.R. Mirza, J. Sehouli, A. Lortholary, K.H. Baumann, F. Hilpert, U. Canzler, L.C. Hanker, J. Pfisterer, P. Harter, A. du Bois
Journal: Annals of Oncology (2024)
904P Analysis of TP63 immunohistochemistry scores (IHC) by primary site and between primary and metastatic tumours in adenoid cystic carcinoma (ACC)
Authors: L. Spurgeon, G. Betts, J. Haigh, K. Patel, L. Feeney, S. Rack, E. Heathcote, K.J. Harrington, R. Metcalf
Journal: Annals of Oncology (2024)
773P Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials
Authors: P. Corbaux, A. Leary, O. Le Saux, O. Colomban, I. Treilleux, C. Genestie, L. Chardin, L. Collet, L. Bengrine Lefevre, M. Auvray Kuentz, M. Martinez, C. Blonz, F. Priou, J. Alexandre, N. Cloarec, C. Lebreton, L. Venat, A.M. Savoye, B. You, I.L. Ray-Coquard
Journal: Annals of Oncology (2024)
777P A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL)
Authors: K. Oda, D. Shintani, M. Mori, N. Matsumura, K. Kato, S. Nagao, M. Kagabu, M. Takenaka, K. Yoshihara, Y. Konno, J. Hamanishi, A. Nishijima, S. Sato, K. Ueda, K. Kashiwabara, T. Aoki, K. Nishimura, K. Tatsuno, H. Aburatani, K. Hasegawa
Journal: Annals of Oncology (2024)
748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
Authors: A. Oaknin, C. Drescher, K. Banda, L. Duska, V. Ribrag, A. Tewari, N.J. Lakhani, L. Eberst, R.D. Harvey, L.M. Manso Sanchez, D. Lorusso, H. Kindler, H.S. Walter, D.G. Illescas, E. Pons-Tostivint, A.G. Thakur, L. Kann, A. Reddy, N. Faulhaber, A. González-Martín
Journal: Annals of Oncology (2024)
754P Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Authors: R. Shapira-Frommer, K. Sudo, K. Harano, L. Mileshkin, R. Perets, M. Song, J. Cohen, Y-F. Huang, H. Ambrose, T. Brier, A. Dosani, P.G. Fraenkel, A. Kmieciak, P. Mitchell, C. Myers, J. Wang, R.I. Odegbami, A. Sykes, S. Turner, F. Meric-Bernstam
Journal: Annals of Oncology (2024)
775P Association between chemotherapy response score (CRS) and tumour homologous recombination deficiency (tHRD) in women with newly diagnosed FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Authors: F. Britton, C. Zhou, G.J. Burghel, H. Schlecht, S. Desai, B. Barnes, A.R. Clamp, J. Hasan, C.L. Mitchell, Z. Salih, R. Edmondson, G.D. Evans, G.C. Jayson, S. Taylor, R.D. Morgan
Journal: Annals of Oncology (2024)
755P Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer
Authors: M.K. Kjeldsen, D.B.S. Grønseth, G-B. Nyvang, C.A. Haslund, S. Malander, M.A. Anttila, G. Lindahl, J. Mäenpää, M. Dimoula, T. Werner, T.Z. Iversen, S. Hietanen, L. Fokdal, H. Dahlstrand, L. Bjorge, M. Rossing, M.R. Mirza
Journal: Annals of Oncology (2024)
756P Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
Authors: J. Park, J-G. Joung, E. Park, J. Lee, M.C. Lim, B-G. Kim, J-W. Kim, S. Shin, S. Kim, C.H. Choi, H.S. Kim, S.Y. Park, J-Y. Lee
Journal: Annals of Oncology (2024)
780P Propensity-score matching analysis for efficacy of platinum-based versus non-platinum chemotherapy in patients with “platinum-resistant” ovarian cancer (PROC): Real-world recent cohort study
Authors: A. Rumyantsev, E.R. Israelyan, I. Pokataev, E. Glazkova, A. Tsareva, A. Ablyametova, A. Letuchikh, E. Ignatova, A. Anokhin, M. Abramov, A. Shevchuk, A. Tyulyandina, S. Tjulandin
Journal: Annals of Oncology (2024)
762P First results from phase II dose expansion cohort of transcon IL-2 β/γ in combination with standard of care chemotherapy for platinum resistant ovarian cancer (PROC) in the IL Believe trial
Authors: O. Yeku, J-Y. Lee, B. Rimmel, S-B. Kim, T. Van Den Mooter, G. Kichenadasse, C. Krapp, S. Slavsky, D. Torrejon Castro, S. Singel, V. Kwatra
Journal: Annals of Oncology (2024)
903P Patterns and predictors of recurrence-free survival (RFS) in salivary gland cancers (SGCs): A Spanish multicenter study
Authors: A-A. Izquierdo Miranda, M. Balsa Pena, S. Tous, J. Canet-Hermida, A. Alay Badosa, I. Quintana, E. Purqueras, M. Goma, A. Marí, C. Viña, A. Quer, X. León, N. Baste Rotllan, F. Cuesta, R.D. Ramírez, P. Castillo, M.S. Bescos, C. Lazaro, D. Azuara, M. Oliva Bernal
Journal: Annals of Oncology (2024)
757P Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study
Authors: J.F. Cueva Banuelos, I. Palacio Vazquez, C. Maximiano Alonso, P. Estevez Garcia, L.M. Manso Sanchez, M. Constenla Figueiras, Y. Garcia Garcia, S. Cros Costa, C. Salvador Coloma, A. Santaballa Bertran, J.G. Cassinello, M. Corbellas Aparicio, S. Hernando Polo, A. De Juan Ferre, A. Herrero Ibañez, E.M. Guerra Alia, J. Fuentes Pradera, M.E. Iriarte Moncho, A. González-Martín
Journal: Annals of Oncology (2024)
752P Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
Authors: T.A. Zwimpfer, A. Pandey, S. Fereday, R.J.B-N. Coelho, L. Twomey, D. Ariyaratne, N. Traficante, F. Jacob, R. Eller, V. Heinzelmann-Schwarz, E.L. Christie, C. Kennedy, G. Au-Yeung, S. Ramus, M. Koebel, B. Nelson, E.L. Goode, A. DeFazio, D.D.L. Bowtell, D.W. Garsed
Journal: Annals of Oncology (2024)
766P A phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC)
Authors: J. Zhu, D. Wang, J. Wang, W. Wang, Q. Li, J. Tang, Y. Huang, R. An, W. Duan, J. Tang, L. Wang, R. Li, D. Wang, Y. Zhang, G. Lou, B. Zhang, W. Di, J. Lin, Y. Wang, R. Yin
Journal: Annals of Oncology (2024)
799MO The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
Authors: L. Pan, Z. Xu, W. Yu, X. Shen, Z. Zhang, Z. Jiao, X. Zhao, M. Hou, X. Du, H. Ma, M. Duan, H. Peng, M. Yang, W. Wang, T. Gong, D. Ding, D. Wang, Z. Xiao
Journal: Annals of Oncology (2024)
829P Flumatinib combined with chemotherapy for newly diagnosed adult with Ph-positive acute lymphoblastic leukemia: A single-center, retrospective observational study
Authors: H. Shuyu, W. Yanan, L. Chao, G. Silin, H. Lijie, M. Jie, W. Feifei, W. Weiqiong, C. Jieke, S. Yufeng, S. Hui, W. Weimin
Journal: Annals of Oncology (2024)
820P Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom’s macroglobulinemia: Outcomes of a population-based analysis
Authors: V. Spiliopoulou, I. Ntanasis-Stathopoulos, M-C. Kyrtsonis, A. Symeonidis, E. Hatjiharissi, N. Giannakoulas, E.G. Spanoudakis, S. Delimpasi, E. Michali, M.D. Michael, A. Vassou, M. Iskas, A. Pouli, E. Vervessou, D. Christoulas, E. Katodritou, E. Terpos, E. Kastritis, M.A.C. Dimopoulos, M. Gavriatopoulou
Journal: Annals of Oncology (2024)
828P Translocation 11;14 is not associated with adverse prognosis in the era of novel anti-myeloma therapeutics
Authors: I. Ntanasis-Stathopoulos, P. Malandrakis, V. Spiliopoulou, A. Briasoulis, D. Fotiou, M.D. Migkou, F. Theodorakakou, N. Kanellias, E. Eleutherakis-Papaiakovou, M. Roussou, E. Kastritis, E. Terpos, M.A.C. Dimopoulos, M. Gavriatopoulou
Journal: Annals of Oncology (2024)
884P Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A German claims data analysis
Authors: T. Kuhnt, N. Kossack, L. Richter, M. Schultze, U. Osowski, L. Henkel, A-C. Gaupel, N. Schoenherr
Journal: Annals of Oncology (2024)
821P Circulating chromosomal alterations in lymphoid malignancies
Authors: R. Griffin, N.J. Boddicker, E.G. Franke, D. Robinson, W. Zhou, S.A. Parikh, A.D. Norman, E. Braggio, S. Kumar, L. Baughn, S. Berndt, J.R. Cerhan, C.M. Vachon, S.L. Slager
Journal: Annals of Oncology (2024)
808MO Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy
Authors: S.A. Mirshahvalad, A. Kohan, R. Kulanthaivelu, Y. Chin, C. Chen, D. Hodgson, R. Kridel, S. Bhella, U. Metser, P. Veit-Haibach
Journal: Annals of Oncology (2024)
774P Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database
Authors: M. Zenatri, E. Martin, M.J. Rodrigues, I.L. Ray-Coquard, L. Gladieff, P-E. Colombo, R. Sabatier, F. Joly Lobbedez, T. De La Motte Rouge, C. Pomel, C. Guillemet, T. Petit, J-D. Fumet, C. Lebreton, L. Rossi, P. Pautier, P. Follana, L. Bosquet, J-S. Frenel, P. Augereau
Journal: Annals of Oncology (2024)
758P Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Authors: E. Zsiros, E.S. Christenson, D. Sohal, S. Manda, S. Fu, A. Martz, M. Zika, S. Kordahi, P. Kothari, S. Kahan, E.A. Barbu, A. Morawski, D. Flies, S.A.R. Langermann, M. Chisamore, U. Guha, H. Myint, D. Mahadevan
Journal: Annals of Oncology (2024)
772P Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study
Authors: J. Sehouli, F. Hilpert, M.K. Welslau, J.P. Grabowski, A. Schneeweiss, A.D. Hartkopf, S. Becker, D. Bauerschlag, P.A. Fasching, C. Brandi, J-K. Rehbein, R.M. Glowik, F. Marmé
Journal: Annals of Oncology (2024)
759P JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies
Authors: Q. Rao, Y. Chen, B. Gao, G. Weng, Z. Zhang, K. Wilkinson, J. Liu, Y. Shu, L. Liu, C. Lan, J.J.W. Park, A. Lin, X. Wang
Journal: Annals of Oncology (2024)
825P Ultra-sensitive cfDNA analysis for minimally invasive measurable residual disease detection and profiling in multiple myeloma
Authors: N. Buenache, A. Martín-Muñoz, Y. Ruiz-Heredia, M. Lasa, L. Notarfranchi, C. Gonzalez, M.T. Cedena, S. Barrio, M.J. Calasanz, M-V. Mateos, L. Rosiñol, J.J. Lahuerta, J. Blade, N. Puig, B. Paiva, J. Martinez-Lopez
Journal: Annals of Oncology (2024)
749P Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study
Authors: L.P. Martin, D. Uyar, A. Madariaga, A.I. Spira, A. Oaknin, R. Schilder, E.M. Guerra Alia, E.P. Hamilton, R.W. Naumann, D. Lorusso, L. Lu, C.J. Berman, A.E. Borgman, J.W. Moroney
Journal: Annals of Oncology (2024)
886P Retrospective multicentric survival analysis of patients receiving TPEx regimen (docetaxel, platinum and cetuximab) as first line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
Authors: L. Libert, C. Abdeddaim, K. Saleh, C. Even, S. Duplomb, J. Dubreuil, A. Rambeau, E. Guiard, Y. Pointreau, N. Olympios, C. Moldovan, E. Lévêque, F. Clatot
Journal: Annals of Oncology (2024)
1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
Authors: A. Passaro, H.A. Yu, D. Nguyen, V.H.F. Lee, R.A. Soo, S.H. Kim, H. Daga, D.S.W. Tan, S-W. Kim, O.J. Juan Vidal, Z. Piotrowska, E.K. Keeton, T. Liu, S. Li, J. Jones, G. Ruiter
Journal: Annals of Oncology (2024)
1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study
Authors: M.E. Pavel, D. Ferone, D. Halperin, S. Myrehaug, K. Herrmann, P.L. Kunz, B. Chasen, J. Capdevila Castillon, S. Tafuto, D-Y. Oh, C. Yoo, S. Falk, T.R. Halfdanarson, I. Folitar, Y. Zhang, W.W. de Herder, S. Singh
Journal: Annals of Oncology (2024)
1387P Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK
Authors: R. Batool, M. Sadiq, Q. Ghafoor, S. Watkins, E.M. Karapanagiotou, E. Josephides, R. Dunn, A. Datta, S. Rahman, N. Mathiyalagan, S. Raza, H. Attia, P. Earwaker, D. Saleh, M. Israr, H.A.M. Hassan, S. Noor, G. Clements, T. Aghadiuno, T. Hafeez
Journal: Annals of Oncology (2024)
1261P Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations
Authors: J. Wang, J. Zhao, J. Fang, Y. Yu, Q. Chu, X. Li, J. Chen, Z. Liu, L. Zhang, L. Wu, W. Zhuang, X. Li, Y. Zhao, L. Xing, L. Liu, C. Bai, X. Dong, Q. Song, R. Wan, X. Fang
Journal: Annals of Oncology (2024)
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
Authors: A.E. Drilon, J.J. Lin, M.L. Johnson, C.S. Baik, L.G. Paz-Ares, B. Besse, J. Mazieres, A. Swalduz, A.R. Minchom, J. Reuss, S. Gadgeel, J.W. Riess, G. Liu, B.J. Solomon, D.R. Camidge, W. Swe, Y. Sun, J. Shen, V.W. Zhu, E. Felip
Journal: Annals of Oncology (2024)
1403P A phase II study of tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: Long-term follow-up outcomes of TD-NICE
Authors: T. Jiang, X. Yan, J. Zhao, J. Lei, Y. Ni, Y. Zhou, X. Wang, H. Qi, L. Gong, H. Liu, F. Tian, Q. Lu, J. Sun, E. Yang, D. Zhong, T. Wang, L. Huang, J. Jiang
Journal: Annals of Oncology (2024)
1150P Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206)
Authors: R. Salazar Soler, A. Scarpa, R.T. Lawlor, A. Sadanandam, S. Tafuto, M. Krogh, A. Teule, R. Garcia-Carbonero, H.J. Klumpen, B. Cremer, I. Sevilla, B.K. Eriksson, E. Mitkina Tabaksblat, J-P. Metges, N.S. Reed, J. Schrader, S. Bozzarelli, M. Venerito, V. Navarro, J. Capdevila Castillon
Journal: Annals of Oncology (2024)
995MO Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade
Authors: A.J. Grippin, S. Copling, A. Kim, E. Young, R. Lohray, E. Chang, R. Kouzy, J. Lewis, X. Wei, W. Rinsurongkawong, J.J. Lee, D. Gibbons, A. Vaporciyan, H.T. Tran, Y.S.B. Kim, J.V. Heymach, J. Zhang, E. Sayour, W. Jiang, S.H.H. Lin
Journal: Annals of Oncology (2024)
768P Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status
Authors: E. Rouleau, I. Soubeyran, V. Haddad, V. Harter, A. Buisson, R. Boidot, L.M. Chevalier, A. Lespagnol, C. Callens, S. Manz, P.J. Lamy, K. Leroy, A. Tallet, O. Laghmari, J. Lehmann-Che, C. Toulas, A. Harlé, E. Pujade-Lauraine, T. De La Motte Rouge, D. Vaur
Journal: Annals of Oncology (2024)
822P Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Authors: L. Deng, Y. Song, Y. Liu, N. Lin, Z. Yao, J. Zhang, W. Meng, Z. Wang, Q. Lu, W. Tian, J. Zhu
Journal: Annals of Oncology (2024)
771P Claudin-6 expression in primary and recurrent epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Authors: D. Shintani, M. Hanaoka, T. Komats, M. Yano, A. Yabuno, S. Yagishita, M. Yasuda, M. Nagata, K. Hasegawa
Journal: Annals of Oncology (2024)
703P Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER
Authors: A.A. Kolawa, R. Ireland, K. Patel, S. Iyengar, A. Arizpe, J. Tiulim, I. Chen, S. Frost, E. Pan, V. Tulpule, D.I. Quinn, S. Daneshmand, A. Schuckman, H. Djaladat, J.S. Hu, V. Cortessis, A.A. D'Souza
Journal: Annals of Oncology (2024)
730P Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Authors: G. Beinse, V. Taly, A. Leary, A. Baures, O. Tredan, B. You, M.J. Rodrigues, L. Gladieff, S. Abadie Lacourtoisie, L. Bengrine Lefevre, P-E. Brachet, C. Lebreton, E. Kalbacher, P. Fournel, J-S. Frenel, F. Selle, R. Largillier, P. Laurent-Puig, F. Joly Lobbedez, J. Alexandre
Journal: Annals of Oncology (2024)
692P Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study
Authors: Y.A. Zhulikov, E.I. Kovalenko, E. Artamonova, E.V. Evdokimova, V. Bohian, M. Gabrava, E. Kolobanova, V.V. Yugay, I.S. Stilidi
Journal: Annals of Oncology (2024)
739P Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA)
Authors: W.R. Grither, M.G. Evans, R. Ali-Fehmi, H. Krause, A. Elliott, C. Mathews, M. Oliver, K. Miller, S. Wei, J. Hechtman, D. Bryant, M. Oberley, M.A. Powell, P.H. Thaker
Journal: Annals of Oncology (2024)